| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2019: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2018: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2017: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Outline of Final Research Achievements |
It is important to establish the therapeutic strategy against sepsis by inhibiting hyperactivation of infllammation with controlling infection. An immunoinhibitory receptor, Allergin-1, is expressed on myeloid cells, transmit an inhibitory signal via ITIM sequence in its cytoplasmic region, and function as immune-checkpoint receptor. We found that Allergin-1-deficiency protects the mice from death by cecal ligation puncture (CLP)-induced sepsis. Further analyses demonstrated that Allergin-1-deficiency promotes IL-10 production by peritoneal macrophages via TLR4 signaling. These observations suggest that Allergin-1 may be a therapeutic targeting molecule in sepsis.
|
